To date, 760 orphan drugs have been approved by US and European agencies to treat nearly 7,000 identified rare diseases. With 80% having a genetic component, genetic testing and the use of its data have become essential ingredients to the successful diagnosis and treatment of rare diseases. Yet incorporating that genetic data into the clinical trials that develop those orphan drugs for treatment is fraught with challenges related to:
- Eligible patient identification and clinical trial enrollment
- Patient recruitment and retention
- Complex regulations and guidelines for genetic testing
Download this white paper today to discover the non-traditional strategies InformedDNA successfully implemented with 4 actual life science clients that helped them to:
- Client 1: Boost eligible patient enrollment by 50%
- Client 2: Identify 12 additional at-risk family members per patient to qualify for their Phase III clinical trial and later-FDA-approved therapy
- Client 3: Maximize the amount of ethically obtained genetic data, while minimizing clinical uncertainty
- Client 4: Secure large patient population for future clinical research opportunities and post-market therapy
By harnessing the power of genetic data, organizations can overcome the barriers that hinder the advancement of life-saving treatments for rare diseases. InformedDNA has partnered with life science clients to implement innovative solutions that have proven effective in patient identification, recruitment, and compliance with regulations.
Download the white paper now to unlock the insights you need to navigate the complexities of incorporating genetics into your clinical trial programs.
